Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous anti-CD19 CAR T cells GLPG5101

A preparation of autologous stem-like early memory T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T cells GLPG5101 specifically recognize and kill tumor cells expressing CD19. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD19 CAR-T cells GLPG5101
Code name:19CP 02
19CP-02
19CP02
GLPG 5101
GLPG-5101
GLPG5101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search